Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
N T-CoV2-1 preliminary data supports regulatory filings for Phase 1 studies Intranasal administration elicits immune responses TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech comp